2019
Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs
Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM. Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs. Frontiers In Oncology 2019, 9: 9. PMID: 30723704, PMCID: PMC6349777, DOI: 10.3389/fonc.2019.00009.Peer-Reviewed Original ResearchPreclinical animal modelsSCID pigsOvarian carcinomaAnimal modelsEar tissueLate-stage diseaseLethal gynecologic malignancyOvarian cancer researchImmunodeficient pigsGynecologic malignanciesCarcinoma cell linesImmunohistochemical phenotypeCytokeratin 7Ovarian cancerXenotransplantation modelNeck musclesOrthotopic modelTumor massOvCa cellsPapillary carcinoma cell lineCarcinomaControl pigsClaudin-4Claudin-3Tumors
2016
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 12238-12243. PMID: 27791010, PMCID: PMC5087050, DOI: 10.1073/pnas.1614120113.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinosarcomaClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHistonesHumansMiddle AgedMutationOvarian NeoplasmsPTEN PhosphohydrolaseTelomeraseTumor Suppressor Protein p53Uterine NeoplasmsConceptsEpithelial-mesenchymal transitionWhole-exome sequencingHistone gene clusterMutational landscapeStable transgenic expressionExcess of mutationsMultiregion whole-exome sequencingHistone genesEvolutionary historyPhylogenetic relationshipsGene clusterHistone H2AChromosome segmentsSeparate lineagesCancer genesGenetic landscapeUterine serous carcinoma cell linesTransgenic expressionGenesCarcinoma cell linesGene TP53Frequent amplificationFrequent deletionsChromosome 6pInvasive properties
2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics 2015, 14: 2519-2526. PMID: 26333383, PMCID: PMC4636465, DOI: 10.1158/1535-7163.mct-15-0383.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell CycleCell Line, TumorCell SurvivalClass I Phosphatidylinositol 3-KinasesCystadenocarcinoma, SerousDose-Response Relationship, DrugDrug SynergismFemaleGene AmplificationHumansImidazolesImmunoblottingMice, SCIDMutationOxazepinesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationQuinolinesReceptor, ErbB-2Uterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neu gene amplificationNeu gene amplificationUSC xenograftsUterine serous carcinomaGene amplificationUterine serous carcinoma cell linesSingle-agent therapyNovel therapeutic optionsWild-type PIK3CADose-dependent increaseIdeal therapeutic targetUSC cell linesCell linesDose-dependent declineFlow cytometry assayG0-G1 phaseCell cycle distributionOncogenic PIK3CA mutationsPercentage of cellsUSC patientsEndometrial cancerAggressive variantSerous carcinomaTherapeutic optionsCarcinoma cell linesPIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. British Journal Of Cancer 2015, 113: 1020-1026. PMID: 26325104, PMCID: PMC4651122, DOI: 10.1038/bjc.2015.306.Peer-Reviewed Original ResearchConceptsUSC cell linesCell linesPIK3CA-mutated tumorsUterine serous carcinomaHER2/neuXenograft mouse modelOncogenic PIK3CA mutationsPrimary HER2Trastuzumab treatmentSerous carcinomaCarcinoma cell linesMechanisms of resistancePIK3CA mutationsTrastuzumab efficacyMouse modelTrastuzumabMouse xenograftsHER2Tumor growthMajor mechanismOncogenic mutationsWild-type cell linesSitu hybridisationSolitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. American Journal Of Obstetrics And Gynecology 2015, 214: 99.e1-99.e8. PMID: 26272866, PMCID: PMC4698047, DOI: 10.1016/j.ajog.2015.08.011.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, BispecificAntigens, NeoplasmAntineoplastic AgentsAscitic FluidCarcinoma, PapillaryCD3 ComplexCD4-Positive T-LymphocytesCell Adhesion MoleculesCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesCytokinesCytotoxicity, ImmunologicEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansLymphocyte ActivationNeoplasms, Cystic, Mucinous, and SerousT-Lymphocytes, CytotoxicUterine NeoplasmsConceptsUterine serous carcinoma cell linesUterine serous carcinomaEpithelial cell adhesion moleculeCell adhesion molecule expressionCarcinoma cell linesChromium release assaysSerous carcinoma cellsPeripheral blood lymphocytesAdhesion molecule expressionCell adhesion moleculeEpithelial cell adhesion molecule (EpCAM) expressionSerous carcinomaAdhesion moleculesBlood lymphocytesMolecule expressionT cellsAscitic fluidCell linesTumor-associated T cellsT cell-mediated killingT-cell activation markersFlow cytometryTumor cellsCarcinoma cellsRobust immunologic responses
2013
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor
English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecologic Oncology 2013, 131: 753-758. PMID: 24012800, DOI: 10.1016/j.ygyno.2013.08.033.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, PapillaryCell Line, TumorCystadenocarcinoma, SerousFemaleGene AmplificationHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MorpholinesMultiprotein ComplexesProtein Kinase InhibitorsReceptor, ErbB-2TOR Serine-Threonine KinasesUterine NeoplasmsConceptsUSC cell linesC-erbB2 gene amplificationUterine serous carcinoma cell linesDual mTORC1/2 inhibitorCarcinoma cell linesC-erbB2Cell linesGene amplificationMTORC1/2 inhibitorsPrimary USC cell linesHER2/neu gene amplificationG0/G1 cell cycle phaseDose-dependent increaseHigh HER-2HER2/neuNeu gene amplificationDose-dependent declinePercentage of cellsUSC patientsHER-2Cell cycle profileDifferential growth inhibitionG1 cell cycle phasePS6 levelsTherapeutic agentsOncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). American Journal Of Obstetrics And Gynecology 2013, 209: 465.e1-465.e9. PMID: 23891627, DOI: 10.1016/j.ajog.2013.07.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicCarcinoma, PapillaryCell Line, TumorClass I Phosphatidylinositol 3-KinasesDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleGene AmplificationGenes, erbB-2HumansIn Situ Hybridization, FluorescenceMiddle AgedMutationPhosphatidylinositol 3-KinasesPyrimidinesTOR Serine-Threonine KinasesConceptsClass I PI3-kinasePI3-kinaseC-erbB2 gene amplificationOncogenic PIK3CA mutationsMTOR kinaseCell linesGene amplificationUterine serous carcinoma cell linesDownstream cellular responsesCarcinoma cell linesUSC cell linesGene mutationsCellular responsesKinaseDifferential growth inhibitionDNA sequencingDirect DNA sequencingMutationsSitu hybridizationUse of GDCGrowth inhibitionExon 9HER2/neu gene amplificationFishPrimary USC cell lines
2011
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation
Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.Peer-Reviewed Original ResearchConceptsCervical carcinoma cellsCervical cancer cellsHuman papillomavirus E6Human cervical carcinoma cellsCarcinoma cellsPrimary cervical cancer cellsCancer cellsPapillomavirus E6Cervical carcinoma cell linesE2 proteinHuman cervical cancer cellsCarcinoma cell linesE7 expressionE7 oncogenesLow passage numberSerum-free conditionsCell surface receptorsSV40 infectionTumor suppressor pathwayCell linesPrimary cellsViral vectorsE6Suppressor pathwayPassage numberHer2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
Todeschini P, Cocco E, Bellone S, Varughese J, Lin K, Carrara L, Guzzo F, Buza N, Hui P, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. British Journal Of Cancer 2011, 105: 1176-1182. PMID: 21915118, PMCID: PMC3208497, DOI: 10.1038/bjc.2011.369.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCulture Media, ConditionedFemaleFlow CytometryGenes, erbB-2HumansImmunohistochemistryImmunotherapyIn Situ Hybridization, FluorescenceMiddle AgedReal-Time Polymerase Chain ReactionTrastuzumabUterine NeoplasmsConceptsAntibody-dependent cell-mediated cytotoxicityTrastuzumab-mediated antibody-dependent cell-mediated cytotoxicityUSC cell linesHER2/neu expressionUSC patientsNeu expressionHER2/ECD levelsCell linesUterine serous carcinoma cell linesCell-mediated cytotoxicityUterine serous carcinomaChromium release assaysHER2/neuFISH-positive tumorsC-erbB2 gene amplificationTrastuzumab-induced cytotoxicityNeu tumorsHealthy womenSerous carcinomaCarcinoma cell linesReal-time PCRTherapeutic effectC-erbB2 genePatientsExpression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
Cocco E, Varughese J, Buza N, Bellone S, Glasgow M, Bellone M, Todeschini P, Carrara L, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Lockwood CJ, Santin AD. Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor. BMC Cancer 2011, 11: 263. PMID: 21693061, PMCID: PMC3141777, DOI: 10.1186/1471-2407-11-263.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Squamous CellCell Line, TumorComplement System ProteinsCytotoxicity Tests, ImmunologicDrug Screening Assays, AntitumorFemaleHuman papillomavirus 16Human papillomavirus 18HumansImmunoconjugatesImmunoglobulin GImmunotherapyInterleukin-2KeratinocytesMolecular Targeted TherapyNeoplasm ProteinsNeovascularization, PathologicPapillomavirus InfectionsRNA, MessengerRNA, NeoplasmThromboplastinUterine Cervical NeoplasmsConceptsCervical cancer cell linesPrimary cervical cancer cell linesCervical carcinoma cell linesCancer cell linesCervical cancerCarcinoma cell linesFactor VII/VIIaTissue factorUterine cervixCell linesImportant worldwide health problemTargeting tissue factorStandard treatment modalitySquamous cell carcinomaExpression of TFWorldwide health problemNovel therapeutic agentsNormal cervical keratinocytesAdenocarcinoma histologyBackgroundCervical cancerCancer refractoryRecurrent diseaseCell carcinomaTreatment modalitiesNovel therapiesHigh-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
Varughese J, Cocco E, Bellone S, Bellone M, Todeschini P, Carrara L, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecologic Oncology 2011, 122: 171-177. PMID: 21453957, PMCID: PMC3104081, DOI: 10.1016/j.ygyno.2011.03.002.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCell Adhesion MoleculesCell Line, TumorDrug Resistance, NeoplasmFemaleFlow CytometryHumansImmunoglobulin GImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedMolecular Targeted TherapyOvarian NeoplasmsRNA, MessengerConceptsAntibody-dependent cellular cytotoxicityOvarian cancer cell linesTrop-2 expressionAnti-Trop-2 antibodyChemotherapy-resistant ovarian cancerPrimary ovarian cancer cell linesCancer cell linesOvarian carcinoma cell linesInterleukin-2Cell surface markersCarcinoma cell linesOvarian cancerCell linesTrop-2Therapeutic agentsChemotherapy-resistant diseaseNovel therapeutic agentsEffect of serumOvarian diseaseControl antibodyHRS7Real-time PCRCellular cytotoxicityCarcinoma specimensRelease assays
2010
Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody
Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody. International Journal Of Gynecological Cancer 2010, 20: 1440-1447. PMID: 21370592, PMCID: PMC3701951, DOI: 10.1111/igc.0b013e3181fb18a1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCarcinomaCell Adhesion MoleculesCell Culture TechniquesCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunotherapyMiddle AgedTreatment OutcomeUterine Cervical NeoplasmsYoung AdultConceptsCervical carcinoma cell linesEpithelial cell adhesion moleculeComplement-dependent cytotoxicityCervical cancer cell linesInterleukin-2Real-time polymerase chain reactionCarcinoma cell linesCell adhesion moleculeCancer cell linesAggressive tumorsPolymerase chain reactionAdhesion moleculesPrimary cervical cancer cell linesCell linesRelease assaysFlow cytometryHighest messenger RNA expressionStandard salvage therapyCell adhesion molecule expressionEffective treatment optionAdhesion molecule expressionChain reactionHuman monoclonal antibodyMessenger RNA expressionEpithelial cell adhesion molecule (EpCAM) expressionHigher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro
Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1Carcinoma, PapillaryCell Line, TumorCystadenocarcinoma, SerousDose-Response Relationship, DrugDrug Screening Assays, AntitumorEpothilonesFemaleHumansPaclitaxelReceptor, ErbB-2TubulinUterine NeoplasmsConceptsLow HER-2/neu expressionHER-2/neu expressionPrimary USPC cell linesUSPC cell linesUterine serous papillary carcinomaSensitivity/resistanceNeu expressionCell linesAggressive endometrial tumorsPromising novel drugSerous papillary carcinomaΒ-tubulin IIIQuantitative RT-PCRPaclitaxel chemotherapyAdverse prognosisCarcinoma cell linesEndometrial tumorsNeu overexpressionPapillary carcinomaUSPC patientsPatupilonePapillary carcinoma cell lineP-glycoproteinNovel drugsPaclitaxelClostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Clear CellAnimalsCarcinoma, PapillaryCarcinoma, Squamous CellChlorocebus aethiopsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleFibroblastsFlow CytometryHumansMembrane ProteinsMiceMice, SCIDOvarian NeoplasmsPeptide FragmentsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSpheroids, CellularTissue DistributionTransplantation, HeterologousTumor Cells, CulturedUterine Cervical NeoplasmsVero CellsConceptsChemotherapy-resistant ovarian cancerClostridium perfringens enterotoxinOvarian cancerOvarian carcinoma cell linesClaudin-3Carcinoma cell linesNovel tumor-homing peptideCarboxy-terminal fragmentTumor cellsResistant ovarian cancer cell linesCell linesNew diagnostic tracersCPE peptideOvarian cancer cell linesResistant ovarian cancer cellsResistant ovarian carcinomaHuman ovarian cancerRelevant animal modelsOvarian tumor cellsOvarian cancer cellsChemotherapy-resistant ovarian cancer cellsHuman epithelial tumorsTime-dependent internalizationCancer cell linesBio-distribution studiesDifferential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro
Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American Journal Of Obstetrics And Gynecology 2010, 203: 162.e1-162.e8. PMID: 20417484, PMCID: PMC2918912, DOI: 10.1016/j.ajog.2010.02.056.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarboplatinCell Line, TumorCell ProliferationCisplatinCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedProbabilityReceptor, ErbB-2Sensitivity and SpecificityUterine NeoplasmsConceptsSingle-agent chemotherapyLow HER-2/neu expressionCell linesHER-2/neu expressionEffective chemotherapy regimensPlatinum-based chemotherapySerous papillary adenocarcinomaHalf-maximum inhibitory concentrationPlatinum compoundsLow half-maximum inhibitory concentrationChemotherapy regimensAdverse prognosisPapillary adenocarcinomaCarcinoma cell linesNeu expressionNeu overexpressionChemotherapy agentsPapillary carcinoma cell line
2009
Serum amyloid A
Cocco E, Bellone S, El‐Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A. Cancer 2009, 116: 843-851. PMID: 20041483, PMCID: PMC2819580, DOI: 10.1002/cncr.24838.Peer-Reviewed Original ResearchConceptsEndometrial endometrioid carcinomaSerum amyloid AEndometrioid carcinoma patientsEndometrioid carcinomaNormal endometrial tissuesSAA concentrationsCarcinoma patientsHealthy womenBenign diseaseEndometrial tissuePolymerase chain reactionLiver-secreted proteinsNormal healthy womenExpression levelsReal-time polymerase chain reactionProtein expression levelsG2 patientsDisease recurrenceCarcinoma cell linesEndometrioid carcinoma tissuesSerum biomarkersAmyloid AHealthy groupBead-based immunoassaySerum amyloidOverexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBlotting, WesternCarcinoma, PapillaryCell Adhesion MoleculesChemotherapy, AdjuvantCystadenocarcinoma, SerousDrug Resistance, NeoplasmEndometrial NeoplasmsEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansImmunoenzyme TechniquesMiddle AgedNeoplasm Recurrence, LocalOrganoplatinum CompoundsOvarian NeoplasmsOvaryPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateTreatment OutcomeTumor Cells, CulturedConceptsRecurrent epithelial ovarian carcinomaEpithelial ovarian carcinomaNormal ovarian tissuesOvarian carcinoma cell linesOvarian carcinomaEpithelial cell adhesion moleculeEp-CAMCarcinoma cell linesCell adhesion moleculeOvarian tissueChemotherapy-resistant epithelial ovarian cancerFlow cytometryCell linesAdhesion moleculesEp-CAM overexpressionStandard treatment modalityCell adhesion molecule expressionOvarian carcinoma patientsEpithelial ovarian cancerPrimary ovarian carcinomasAdhesion molecule expressionSurface expressionAntibody-mediated therapyHuman monoclonal antibodyEpithelial cell adhesion molecule (EpCAM) expressionDevelopment and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas
Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, PapillaryCell Line, TumorCell SeparationClaudin-3Enzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene LibraryHumansImmunoglobulin FragmentsMembrane ProteinsMicroscopy, ConfocalOvarian NeoplasmsSelf-Sustained Sequence ReplicationSensitivity and SpecificitySurface Plasmon ResonanceUterine Cervical NeoplasmsConceptsClaudin-3Uterine serous carcinoma cell linesSerous papillary carcinomaHuman antibody phage display libraryNovel therapeutic targetEnzyme-linked immunosorbent assayEnzyme-linked immunosorbentHuman single-chain antibody fragmentAntibody phage display libraryCarcinoma cell linesUterine carcinomaNovel antitumor agentsPapillary carcinomaTherapeutic targetSingle-chain antibody fragmentHuman antibodiesHuman malignanciesImmunosorbent assayConformational epitopesPhage display libraryCarcinomaCell linesSurface immunofluorescenceCell surface immunofluorescenceAntitumor agents
2006
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas
Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerous papillary carcinomaPapillary carcinoma patientsCarcinoma patientsEndometrioid carcinomaPapillary carcinomaKallikrein 10Benign diseaseSecretion levelsEndometrioid carcinoma patientsNormal healthy femalesTumor culturesSerous papillary tumorsCell biopsyPrimary endometrioid carcinomaNon-cancer groupExpression levelsReal-time polymerase chain reactionGene expression levelsPrimary tumor culturesAggressive variantHealthy womenCarcinoma cell linesPapillary tumorsEndometrial tumors
1999
Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix
SANTIN A, HERMONAT P, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Obstetrics And Gynecology 1999, 94: 78-82. DOI: 10.1097/00006250-199907000-00015.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorSquamous cell carcinomaEndothelial growth factorVascular endothelial growth factor (VEGF) secretionSquamous cell linesUterine cervixCell carcinomaGrowth factor secretionGrowth factorFactor secretionCell linesSensitive enzyme-linked immunosorbentSignificant differencesEnzyme-linked immunosorbentCervical carcinoma cell linesImmunosuppressive cytokinesHistologic typeCervical cancerCarcinoma cell linesCervical tumorsBiologic behaviorHematogenous metastasisAdenocarcinomaCervixRadiation treatment